Kiniksa Pharmaceuticals International (KNSA) Net Margin (2021 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Net Margin came in at 10.44% in Q2 2026, down 93.0% YoY from 149.14% in Q2 2025, and down 0.98% on a QoQ basis from 10.54% in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Net Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 6 years of Net Margin data on file, last reported at 10.44% in Q2 2026.
- Quarterly Net Margin fell 93.0% year-over-year to 10.44% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 9.59% (up 869.0% YoY) and the FY2025 annual result came in at 8.71%, up 1891.0% from the prior year.
- Net Margin eased to 10.44% in Q2 2026, from 10.54% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 226.05% in Q3 2022 to a low of 78.32% in Q1 2022.
- A 5-year average of 3.26% and a median of 5.43% in 2024 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin surged 47858 bps — and 2023, when it slumped 24671 bps.
- Tracing KNSA's Net Margin over 5 years: stood at 59.7% in 2022, then increased by 1 bps to 59.05% in 2023, then jumped by 88 bps to 7.25% in 2024, then jumped by 197 bps to 7.02% in 2025, then soared by 49 bps to 10.44% in 2026.
- The last three Net Margin figures came in at 10.44% (Q2 2026), 10.54% (Q1 2026), and 7.02% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -13.91% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 9.28% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.51% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -3.16% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.06% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.95% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.57 Bn | 220.03 Mn | 10.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.44% |
| Mar 31, 2026 | 10.54% |
| Dec 31, 2025 | 7.02% |
| Sep 30, 2025 | 10.19% |
| Jun 30, 2025 | 11.37% |
| Mar 31, 2025 | 6.20% |
| Dec 31, 2024 | -7.25% |
| Sep 30, 2024 | -11.31% |
| Jun 30, 2024 | -3.60% |
| Mar 31, 2024 | -22.17% |
| Dec 31, 2023 | -59.05% |
| Sep 30, 2023 | -20.66% |
| Jun 30, 2023 | 20.95% |
| Mar 31, 2023 | -25.38% |
| Dec 31, 2022 | -59.70% |
| Sep 30, 2022 | 226.05% |
| Jun 30, 2022 | -74.08% |
| Mar 31, 2022 | -78.32% |
| Dec 31, 2021 | -235.15% |
| Sep 30, 2021 | -252.53% |